Mark G Foletta - Net Worth and Insider Trading
Mark G Foletta Net Worth
The estimated net worth of Mark G Foletta is at least $28 Million dollars as of 2024-05-13. Mark G Foletta is the Director of DexCom Inc and owns about 218,416 shares of DexCom Inc (DXCM) stock worth over $28 Million. Mark G Foletta is the Director of AMN Healthcare Services Inc and owns about 8,573 shares of AMN Healthcare Services Inc (AMN) stock worth over $469,029. Mark G Foletta is also the EVP & CFO of Tocagen Inc and owns about 1,003 shares of Tocagen Inc (TOCA) stock worth over $18,957. Besides these, Mark G Foletta also holds Regulus Therapeutics Inc (RGLS) . Details can be seen in Mark G Foletta's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark G Foletta has not made any transactions after 2024-02-29 and currently still holds the listed stock(s).
Transaction Summary of Mark G Foletta
Mark G Foletta Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark G Foletta owns 6 companies in total, including DexCom Inc (DXCM) , Enanta Pharmaceuticals Inc (ENTA) , and AMN Healthcare Services Inc (AMN) among others .
Click here to see the complete history of Mark G Foletta’s form 4 insider trades.
Insider Ownership Summary of Mark G Foletta
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
DXCM | DexCom Inc | 2021-12-01 | director |
ENTA | Enanta Pharmaceuticals Inc | 2022-03-03 | director |
AMN | AMN Healthcare Services Inc | 2024-02-29 | director |
2017-04-12 | EVP & Chief Financial Officer | ||
2015-08-13 | director | ||
2015-08-18 | Interim CFO |
Mark G Foletta Latest Holdings Summary
Mark G Foletta currently owns a total of 4 stocks. Among these stocks, Mark G Foletta owns 218,416 shares of DexCom Inc (DXCM) as of December 1, 2021, with a value of $28 Million and a weighting of 98.27%. Mark G Foletta owns 8,573 shares of AMN Healthcare Services Inc (AMN) as of February 29, 2024, with a value of $469,029 and a weighting of 1.66%. Mark G Foletta also owns 1,003 shares of Tocagen Inc (TOCA) as of May 28, 2019, with a value of $18,957 and a weighting of 0.07%. The other 1 stocks Regulus Therapeutics Inc (RGLS) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Mark G Foletta
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
DXCM | DexCom Inc | 2021-12-01 | 218,416 | 127.05 | 27,749,753 |
AMN | AMN Healthcare Services Inc | 2024-02-29 | 8,573 | 54.71 | 469,029 |
TOCA | Tocagen Inc | 2019-05-28 | 1,003 | 18.90 | 18,957 |
RGLS | Regulus Therapeutics Inc | 2015-08-13 | 83 | 2.21 | 183 |
Holding Weightings of Mark G Foletta
Mark G Foletta Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark G Foletta has made a total of 11 transactions in DexCom Inc (DXCM) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in DexCom Inc is the sale of 8,000 shares on December 1, 2021, which brought Mark G Foletta around $281,415.
According to the SEC Form 4 filings, Mark G Foletta has made a total of 4 transactions in AMN Healthcare Services Inc (AMN) over the past 5 years, including 1 buys and 3 sells. The most-recent trade in AMN Healthcare Services Inc is the acquisition of 500 shares on February 29, 2024, which cost Mark G Foletta around $28,450.
According to the SEC Form 4 filings, Mark G Foletta has made a total of 1 transactions in Tocagen Inc (TOCA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Tocagen Inc is the acquisition of 333 shares on May 28, 2019, which cost Mark G Foletta around $21,500.
More details on Mark G Foletta's insider transactions can be found in the Insider Trading History of Mark G Foletta table.Insider Trading History of Mark G Foletta
- 1
Mark G Foletta Trading Performance
GuruFocus tracks the stock performance after each of Mark G Foletta's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark G Foletta is -4.14%. GuruFocus also compares Mark G Foletta's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark G Foletta within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark G Foletta's insider trading performs compared to the benchmark.
Performance of Mark G Foletta
Mark G Foletta Ownership Network
Ownership Network List of Mark G Foletta
Ownership Network Relation of Mark G Foletta
Mark G Foletta Owned Company Details
What does DexCom Inc do?
Who are the key executives at DexCom Inc?
Mark G Foletta is the director of DexCom Inc. Other key executives at DexCom Inc include EVP & Chief Legal Officer Micheal Jon Brown , * Matthew Vincent Dolan , and Chief Human Resources Officer Sadie Stern .
DexCom Inc (DXCM) Insider Trades Summary
Over the past 18 months, Mark G Foletta made no insider transaction in DexCom Inc (DXCM). Other recent insider transactions involving DexCom Inc (DXCM) include a net sale of 20,032 shares made by Steven Robert Pacelli , a net sale of 31,284 shares made by Sadie Stern , and a net sale of 329,692 shares made by Kevin R Sayer .
In summary, during the past 3 months, insiders sold 214,480 shares of DexCom Inc (DXCM) in total and bought 0 shares, with a net sale of 214,480 shares. During the past 18 months, 561,776 shares of DexCom Inc (DXCM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 561,776 shares.
DexCom Inc (DXCM)'s detailed insider trading history can be found in Insider Trading Tracker table.
DexCom Inc Insider Transactions
Mark G Foletta Mailing Address
Above is the net worth, insider trading, and ownership report for Mark G Foletta. You might contact Mark G Foletta via mailing address: Amylin Pharmaceuticals Inc, 9360 Towne Centre Dr, San Diego Ca 92121.